PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021
PR: Heidelberg Pharma Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference and Participation at Various Conferences
PR: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US
PR: Paul Ehrlich Institute Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
PR: Heidelberg Pharma Announces Participation at Various Conferences
PM: Annual General Meeting 2021 of Heidelberg Pharma Approves All Proposed Resolutions
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2021
PR: Heidelberg Pharma to Present New Data on its Proprietary ATAC Technology Platform at the AACR Annual Meeting 2021
PR: Heidelberg Pharma announces financial figures for fiscal year 2020 and provides business update
AH: Heidelberg Pharma AG Secures Financing Commitment From its Main Shareholder dievini
PR: Heidelberg Pharma and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine
AH: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101
